https://www.selleckchem.com/products/acy-738.html
Various miRNAs displayed differential expression in parental versus osimertinib-refractory NSCLC cells. miRNA-inhibitory screening revealed miR-494-3p to partially confer resistance to osimertinib . Expression of miR-494-3p was significantly elevated in plasma sampled at disease progression compared to plasma sampled at treatment baseline in a cohort of 21 EGFR T790M-mutation positive NSCLC patients receiving osimertinib. Our results highlight the need for further therapeutic exploration of miR-494-3p in models of -mutant NSCLC. Our res
Aimer
Commentaire
Partagez
